LA-ADTRAN
15.8.2024 14:01:35 CEST | Business Wire | Press release
Adtran today announced that PhireLink has deployed its open and intelligent fiber access technology to bring high-quality broadband to some of Louisiana’s most underserved rural communities. The deployment features Adtran’s Mosaic One software-as-a-service and its Intellifi® connected home solution to support a robust end-user experience. Using Adtran’s AI-driven platform, PhireLink is rapidly scaling a highly efficient, future-facing network capable of delivering critical public services, such as remote learning and telemedicine, and stimulating economic growth across the region.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240815958625/en/
Adtran’s networking technology is helping PhireLink deliver high-speed broadband to rural communities across Louisiana. (Photo: Business Wire)
“We selected Adtran for its open, scalable technology. Our new solution helps us bring dependable, high-speed broadband to more rural communities across Louisiana,” said Glen F. Post, III, CEO of PhireLink. “Working in close collaboration with Adtran’s team, we are not just constructing a network. We’re taking a crucial step towards bridging the digital divide, providing the broadband access needed to invigorate local economies and drive sustained improvements in quality of life.”
Mosaic One empowers PhireLink to enhance operational efficiency, minimize the need for on-site visits, and effectively engage with communities by utilizing materials tailored to local market needs. The end-to-end Combo PON solution also features Adtran’s scalable 10Gbit/s optical line terminal and its SDX 600 Series optical network terminals. What’s more, Adtran’s connected home solution, Intellifi®, is being harnessed in combination with Adtran’s SDG 800 Series Wi-Fi 6 gateways to provide a comprehensive in-home Wi-Fi experience. PhireLink’s customer service representatives can use the platform to resolve connectivity issues remotely, further streamlining operations and ensuring an exceptional customer experience.
“Bridging the digital divide isn’t just a case of deploying the latest and greatest hardware and software. You also need to work closely with clients to overcome challenges unique to each deployment. This is where Adtran excels. We listen to what our clients need and respond with tailored solutions that get the best out of our innovation and give subscribers a great user experience,” commented John Scherzinger, GM of Americas sales at Adtran. “Working closely with PhireLink, we’ve ensured more people in the Slidell area have access to fast and reliable fiber-based internet. But it doesn’t end there. Our Intellifi® cloud-managed Wi-Fi platform enables subscribers to gain better control, personalize and secure their Wi-Fi networks.”
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
About PhireLink
PhireLink is a broadband internet service provider delivering high-quality, high-speed internet across rural America. At PhireLink, we’re more than just an internet provider — we’re neighbors, dedicated to bringing the power of high-speed connectivity to every corner of the communities we serve. We're driven by one simple goal: level the playing field and ensure everyone, no matter where they live, has access to the limitless opportunities the internet provides. To learn more, visit PhireLink.com.
Published by
ADTRAN Holdings, Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240815958625/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom